Richard Pollard, M.D.

Richard Byrd Pollard, M.D.


Infectious Diseases

Internal Medicine


Internal Medicine


  • Professor
To see if Richard Byrd Pollard is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

CARES Clinic

1500 21st St.
Sacramento, CA 95817
Driving Directions

Primary Phone:

Patient Support Services Building

4150 V Street, Suite G500
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Phone: 916-734-3815
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

My philosophy of care is comprehensive primary care of HIV-infected patients and patients with other infectious diseases.

Clinical Interests

Dr. Pollard’s clinical research includes usage of new antiviral drugs, the care of HIV-infected patients, HIV vaccines as well as clinical immunology. Pollard’s research interests include immunology of viral infections, immune responses to HIV, CMV, HPV, and VZV as well as immunologic non-responders.


Infectious Diseases

Center/Program Affiliation

Northern California Center for AIDS Research


M.D., University of Maryland School of Medicine, Baltimore, Maryland, 1970


Emory University , Atlanta, Georgia, 1973-75


Stanford University Medical Center, Stanford, California, 1975-78

Board Certifications

American Board of Internal Medicine, 1975

Professional Memberships

American Association of Immunologists

American College of Physicians, Fellow

Infectious Diseases Society of America, Fellow

Sigma Xi

Honors and Awards

Best Doctors in America, 2010

Best Doctors in America, 2009

Best Doctors in America, 2007

Select Recent Publications

Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, and Pollard RB. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. JAIDS, 2013;64(4): 351-359.


Nagy LH, Grishina I, Macal M, Hirao LA, Hu WK, Sankaran- Walters S, Gaulke CA, Pollard RB, Brown J, Suni M, Baumler AJ, Ghanekar S, Marco ML, Dandekar S. Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal lactobacillus. PLoS ONE, 2013;8(8): e72789.

Kalayjian RC, Spritzler J, Matining RM, Fiscus SA, Gross BH, Francis IR, Pollard RB, Lederman MM, and Landay A. Older HIVinfected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS, 2013; 27(10): 1563-1571.

Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li XD, Dotterweich W, Pollard RB, Asmuth DM, Berglund L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013;33(2): 387-392.

Allen ME, Brown J, Karakas SE, and Pollard RB. Refractory AIDS cholangiopathy: metabolic complications and the role of plasmapheresis. AIDS, 2013;27(7): 1193–1194.

Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks S, Shacklett BL. HIV+ Viremic Slow Progressors Maintain Low Regulatory T-Cell Numbers in Rectal Mucosa but Exhibit High T-cell Activation. AIDS Research and Human Retroviruses, 2013;29(1): 172-177.

Hulgan t, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB for the AIDS Clinical Trials Group. T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384. PLoS One, 2012;7(8): e43803.

Hayes TL, Asmuth DM, Critchfield JW, Knight TH, McLaughlin BE, Yotter T, McConnell DH, Garcia JC, Pollard RB, Shacklett BL. Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa. AIDS, 2012;27: 867-877.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B,Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, MoyleG, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B,Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, SommerfeltMA, Wendel-Hansen V, and Sørensen B. Safety and efficacy of thepeptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial. The Lancet, 2014;14(4):291-300.


Brown J, Burger H, Weiser B, Pollard RB, Li XD, Clancy LJ, Baumann R, Rogers A, Hamdan HB, Pesana RL, and Kagan RM. A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects. AIDS Research and Therapy, 2014;11(14): 1-7.